Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study of Apatinib in Locally Advanced or Metastatic Radioactive Iodine-refractory Differentiated Thyroid Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 14 Apr 2023
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Thyroid cancer
- Focus Therapeutic Use
- Acronyms REALITY
- 11 Apr 2023 Planned End Date changed from 1 Jul 2022 to 31 Dec 2023.
- 07 Jun 2022 Results (n=92) of post-hoc analysis assessing the association between baseline characteristics and survival endpoints, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
- 09 Aug 2021 Planned End Date changed from 1 Jun 2021 to 1 Jul 2022.